Engineered immune cells take aim at childhood cancers in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants age ≤ 26 years at the time of consent for study participation; the first 2 participants enrolled and treated with CAR T cells in both Arms A and B will be ≥ 15 years. and ≤ 26 years at time of consent for study participation * Histologically diagnosed malignant, non-primary CNS solid tumor * Evidence of refractory or recurrent disease * Lansky or Karnofsky score ≥ 50 * Life expectancy ≥ 8 weeks * Recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy and radiotherapy * If no apheresis product or usable T cell product is available, all chemotherapy has been discontinued ≥ 7 days prior to enrollment * If no apheresis or usable T cell product is available, all biologic therapy has been discontinued ≥ 7 days prior to enrollment * If no apheresis product or T cell product is available, all systemic corticosteroid therapy has been discontinued ≥ 7 days prior to enrollment (physiologic replacement dosing is allowed) * If no apheresis product or usable T cell product is available, at least 3 half-lives or 30 days (whichever is shorter) from time of last dose of anti-tumor directed antibody therapy (including checkpoint inhibitor) at time of enrollment * If no apheresis product or usable T cell product is available, at least 6 weeks post last dose of myeloablative therapy and autologous and/or allogeneic stem cell transplant, or non-myeloablative therapy and allogeneic stem cell transplant (all timed from stem cell infusion). Participants who receive autologous stem cell infusion following non-myeloablative therapy are eligible once all other eligibility requirements are met. * If no apheresis product or usable T cell product is available, participants who have received genetically modified cell therapy must be at least 30 days from most recent cell infusion prior to enrollment * If no apheresis product or usable T cell product is available, participants with neuroblastoma must be at least 12 weeks from I131 MIBG therapy. * Adequate organ function * Adequate laboratory values * Participant is able to tolerate apheresis (including placement of temporary apheresis catheter, if necessary), or already has an apheresis product available for use in manufacturing. * Participants of childbearing potential must agree to use highly effective contraception Exclusion Criteria: * Presence of active malignancy other than primary malignant solid tumor diagnosis * Current relevant CNS pathology * Receiving external beam radiation therapy at time of enrollment * Presence of active GVHD, or receiving immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to enrollment * Participant is pregnant or breastfeeding * Participant has presence of active severe infection * Participant has presence of any condition that, in the option of an investigator, would prohibit the participant from undergoing treatment under this protocol * Participant has primary immunodeficiency syndrome * Unwilling or unable to provide consent/assent for participation in the study and 15 year follow up period